Global Nuclear Medicine Market Forecast
- Nuclear medicine market size worth around US$5.2 Bn (2022) likely to rise high to reach US$11.14 Bn by 2030-end
- Market valuation all set for a strong rise at a CAGR of 11.5% between 2023 and 2030
Major Report Findings - Fairfield's Perspective
- The increase in the frequency and persistence of cardiac and cancer disorders, as well as creative approaches to the Mo-99 supply-demand imbalance, are all mentioned as factors in the expansion of the nuclear medicine market.
- Since nuclear medicine is essential for identifying and treating diseases, it is projected that the rising prevalence of various ailments will propel the growth of the nuclear medicine market over the projected period.
- The market's growth is expected to be constrained by its short shelf lives, hospital budget restrictions, and pricey equipment.
- In 2022, the PET applications category dominated the industry. This has been made possible by the growing awareness of early detection, the high prevalence of cancer, and the advantages of diagnosis in the treatment and management of various cancer types.
- In terms of market share for nuclear medicine globally, the therapeutic nuclear medicine segment is anticipated to dominate. The growth can be linked to elements like the relative efficacy of the treatments, the benefits of various treatment alternatives, and market players' growing interest in therapeutic items due to their strong emphasis on clinical studies.
- In 2022, the brachytherapy procedures category controlled the market. During the forecast period, a combination of factors—including rising cancer incidence, technological developments, and a large increase in brachytherapy adoption—is anticipated to propel the sector’s expansion.
- The North American region is anticipated to account for the highest share of the worldwide nuclear medicine market. The large number of nuclear medicine procedures, the reliable healthcare system, and the increased investment in R&D activities are responsible for the region's considerable market share.
- The market for nuclear medicine is expanding in Asia Pacific. Due to the growing demand for nuclear medical treatments and increased industry investment, the Asia Pacific region is expected to have the biggest rise.
A Look Back and a Look Forward - Comparative Analysis
The market is expanding on the back of a strong product pipeline and supportive government programs to expand access to nuclear medicine. A favourable reimbursement environment for radiopharmaceuticals is projected to boost market expansion. The application domains for radiopharmaceuticals are expanding, and as a result, their demand and market share are expected to increase throughout the forecasted period.
The market witnessed staggered growth during the historical period 2018 – 2022. Nuclear medicine was in high demand due to the rise in cardiovascular disorders among the elderly population. Additionally, there had been an increase in the number of cancer patients worldwide, which is a serious condition that necessitates the use of nuclear medications.
It has been predicted that the sector will benefit in the next years from the development of nuclear medicine centres, which will render nuclear medicine therapies accessible to everyone. As a direct result of these advancements in medical technology, more people will get PET and Single-Photon Emission Computed Tomography (SPECT) scans. To increase the usage of radiopharmaceuticals in new ways, research is being done.
Key Growth Determinants
- Increasing Incidence and Prevalence of Target Conditions
A major factor promoting market expansion is the rising incidence of cardiovascular disease and cancer. Most of the cases can be prevented with the help of early detection and treatment, which is where nuclear medicine can play a vital role.
According to the American Heart Association's 2022 projections, 19.1 million deaths worldwide in 2020 were attributable to CVD. Age-adjusted mortality per 100,000 people was 239.8, and age-adjusted prevalence per 100,000 people was 7354.1.
Due to the importance of nuclear medicine in the detection and treatment of disease, it is anticipated that the rising prevalence of a large number of ailments will fuel market expansion throughout the projection period.
- Expanding Application for Early Disease Detection
Medical applications for nuclear imaging techniques include identifying problems of the central nervous system, treating intracranial tumours and arteriovenous malformations, and assisting in the diagnosis of heart and breast diseases. These methods precisely identify molecular activity, making it possible to identify diseases early and evaluate treatments.
Nuclear medicine is used in therapeutic and diagnostic processes to identify many ailments, primarily heart diseases, using SPECT scanning systems and PET scanners. During the projected period, the worldwide nuclear medicine market is anticipated to rise because of the expanding use of nuclear medicine for early disease detection.
- Ascending Chronic Disease Incidence
Chronic conditions like cardiovascular illness, cancer, respiratory problems, neurological issues, and metabolic disorders are becoming more commonplace on a global scale at a worrying rate. According to the Lymphoma Research Foundation, lymphoma is the most prevalent disease in both children and adults and affects over 100,000 Americans annually.
The Global Burden of Diseases suggests that cardiovascular disease is one of the major causes of death. Around 35 million people also suffer from heart-related conditions, which is increasing demand for nuclear medicines for both diagnostic and therapeutic uses.
Nuclear medicine is highly sought after because of its wide range of medical diagnostic procedures and applications, including the detection of the predominate lymph nodes, the drainage of malignant lymphocytes in the incidence of lymphoma, and functional cardiac imaging used to diagnose ischemic heart disease.
Major Growth Barriers
- High Price Points of Hybrid Imaging Devices
Hybrid imaging device adoption is hampered by the high costs associated with them, which also prompts doctors to prefer less expensive conventional imaging systems. For instance, SPECT gamma cameras are priced between US$0.4 Mn and US$0.6 Mn, and PET/CT scanners cost around US$2 Mn. Limited uptake is also a problem for the pricey SPECT/CT hybrid imaging devices, particularly in developing nations.
- Short Half-Life of Radiopharmaceuticals
A nuclear medicine shelf-life mostly depends on the radioisotope's half-life and the radionuclide's composition. Tc-99m, for instance, loses radioactivity after 6 hours in SPECT diagnosis, whereas 1-123 and 1n-111 isotopes should be employed within 13 and 67 hours, respectively.
Radiochemical purity is reduced to an undesirable level by not using radioisotopes within the allotted shelf-life due to radiation and chemical decomposition, which could be fatal during diagnosis and treatment.
Additionally, because nuclear medicine has a shorter half-life, hospitals must produce their own nuclear medicine on-site in cyclotrons or generators, which drives up the cost of capital for hospitals.
Key Trends and Opportunities to Look at
- Fostering Research Activity
Due to increased research and development efforts to broaden hybrid imaging applications, the worldwide nuclear medicine market is anticipated to grow. The widespread use of SPECT and PET/CT systems in oncology, notably in the US, is what spurs R&D efforts to extend the application of hybrid imaging.
The goal of the research is to expand the use of dual optical and PET/CT probes for the non-invasive detection of atherosclerotic plaque inflammation. To identify people who are at a high risk of developing early atherosclerosis, SPECT hybrid imaging is useful.
- Robust and Strong Pipelines
The market's companies put a steady emphasis on the creation of nuclear medicine treatments. Global demand for this therapy option is being driven by the therapeutic impact it has compared to other medicines. The demand for market therapeutics is also predicted to expand in nations with a high cancer burden due to reasons like the development of more sophisticated therapeutic applications and success rates in the treatment of cancer and other ailments.
- Technological Advancements
Compared to other pharmacological products, the use of nuclear medicines was still in its infancy in the healthcare industry during the beginning of the 1990s. Today, however, it is becoming more popular and in greater demand in line with the developments and improvements in neurology and oncology diagnosis and treatment, which are also creating new growth prospects for market participants.
How Does the Regulatory Scenario Shape this Industry?
Extreme caution must be exercised during the production, administration, storage, and disposal of radionuclides due to their intrinsic danger and the related worry about radiation safety for patients and those handling them. Therefore, it is necessary to apply regulatory criteria to improve the radiopharmaceuticals' quality, safety, and potency.
The Cosmetic and Drug Act of 1940 and other regulations control the pharmaceutical businesses in India, and the EANM and USFDA regulations are followed in Europe and the USA. Using this guideline makes it easier to improvise and lowers the threshold for submitting information to regulatory agencies.
Licenses are published by the Nuclear Regulatory Commission (NRC) for the use of byproduct material in healthcare settings. The specialised license with limited scope is the one commonly sought for diagnostic nuclear medicine purposes. This kind of license is given by the NRC to medical institutes and private or group practices.
Atomic Energy (Radiation Protection) Rules, 2004, and AERB Safety Codes [AERB/RF-SC/MED-1] specify the regulatory requirements that must be met before a radiotherapy facility or nuclear medicine infrastructure in India. The user institute must also obtain the necessary regulatory approval from the AERB in accordance with the AERB Safety Guide for Consenting Process for Radiation Facilities (AERB/SG/G-3).
Fairfield’s Ranking Board
Top Segments
- PET Applications Retain Dominance
The PET applications segment dominated the market in 2022. In PET Applications, the oncology subsegment acquired a major market share. Imaging methods are widely used to diagnose cancer all around the world. The rising incidence of cancer, the advantages of early detection in treating and controlling cancer in all its forms, and the expanding public awareness of the significance of diagnosis all contribute to this.
Furthermore, the diagnostic applications category is projected to experience the fastest market growth. This is because SPECT applications are expanding, healthcare awareness is rising, and more money is being invested in the research and development of innovative nuclear medications for the treatment of cancer.
During the projection period, the cardiology sub-segment is expected to grow at a significant CAGR. The rising use of nuclear medications for the detection and treatment of cardiovascular disorders is blamed for the segment's growth.
- Therapeutic Nuclear Medicine Leads
In 2022, the therapeutic nuclear medicine category dominated the industry. The segment's robust product pipeline and the approval and commercialisation of nuclear medicine treatments may both contribute to the segment's growth. Currently, the most often used alpha emitter in therapeutics is radium (Ra-223). The creation of potential radioisotopes like Terbium (Tb-149), Bismuth (Bi-212), and Actinium (Ac-225) is expected to accelerate the sector's growth.
Due to the large patient population and accessibility of cutting-edge technologies like SPECT and PET, the diagnostic nuclear medicine category is predicted to expand significantly throughout the projected time. The segment is expanding because of the large variety of radiotracers now used in the diagnosis of tumours and technological improvements.
- Demand for Brachytherapy Procedures Higher
The brachytherapy procedures segment dominated the market in 2022. Brachytherapy is used to treat cancers in different parts of the body, including the head and neck, as well as tumours of the prostate, cervix, breast, and scalp. The rise in elderly populations, rise in cancer prevalence, and rise in cancer prevalence are the main factors driving the sector for brachytherapy.
The alpha emitter procedures category is expected to experience the fastest growth within the forecast time frame. The segment is expanding on account of various causes, such as growing public awareness of the potential advantages of targeted alpha treatment and an increase in the number of cancer and cardiac patients.
Additionally, alpha particles have an advantage in targeted therapy because of their unusually strong cell-killing potential. This is known as targeted anticancer or alpha therapy (TAT), which is increasingly used in the treatment of cancer.
Regional Frontrunners
North America Takes up the Largest Share of Market Revenue Pie
A sizable portion of the population in the area suffers from cancer and cardiovascular disorders. The market is expanding due to the simple accessibility of radiopharmaceuticals from regional manufacturers, physician adoption of nuclear medicine in a variety of diagnostic and therapeutic procedures, and technological advancements.
The US dominates the local market. This is explained by the increased emphasis on home production of radiopharmaceuticals and nuclear drugs like Technetium (Tc 99m). The FDA in the United States has also approved a number of nuclear medications, including Alpha emitters and injections of radium Ra 223 dichloride, for the treatment of prostate cancer.
The market is also growing due to the growing demand for patient screening and the creation of high-performance medical diagnostic technologies.
Asia Pacific Develops the Most Favourable Environment for Market Expansion
The market for nuclear medicines in the Asia Pacific is primarily driven by rising consumer knowledge of nuclear medicine, rising rates of cancer and cardiovascular disease, rising healthcare costs, and expanding SPECT and PET applications.
As disposable incomes increase across the region, more people are becoming conscious of diagnostic imaging techniques and how to use them to effectively identify and treat a variety of illnesses. China has made significant strides in the R&D of nuclear medicine over more than 50 years of development.
Nuclear imaging procedures are being performed in greater numbers because of the rising prevalence of chronic diseases in developed nations like India, China, and Japan, which is further fuelling the expansion of the nuclear medicine market in the Asia Pacific region.
Fairfield’s Competitive Landscape Analysis
The global nuclear medicine market is consolidated, with fewer significant companies present in every country. To increase their global footprint, the major firms are launching new items and enhancing their distribution networks. In addition, Fairfield Market Research anticipates that during the next few years, there will be further market consolidation.
Who are the Leaders in Global Nuclear Medicine Space?
- Advanced Accelerator Applications
- Norgine B.V.
- Blue Earth Diagnostics Ltd.
- Curium Pharma
- Digirad Corporation
- Jubilant Radiopharma
- Karyopharm
- Lantheus Holdings, Inc.
- Northstar Nuclear Medicine
- Precirix NV
- Sinotau Pharmaceuticals
- Solcom
- Zionexa
- Cardinal Health
- Bracco Diagnostic Inc.
Recent Company Developments
New Product Launches
- May 2022: The Turku PET Centre debuted the most recent whole-body PET scanner. This new generation of medical imaging technologies provides fresh approaches for examining disorders that affect the entire body rather than just one organ. Examples of such illnesses include diabetes, coronary artery disease, and multiple sclerosis. The patient will experience less radiation and a quicker scanning process thanks to the use of the new device.
- February 2022: Applied Molecular Therapies has introduced 177Lu(n.c.a.)-PSMA-Therapy, a molecularly targeted radiopharmaceutical for the treatment of prostate cancer. The molecular targeted radiopharmaceutical 177Lu(n.c.a.)-PSMA-Therapy binds to the PSMA (Prostate Specific Membrane Antigen) in males with prostate cancer. Only the TGA special access program and clinical studies will have access to 177Lu(n.c.a.)-PSMA-Therapy.
Partnership Agreements
- August 2021: NorthStar Medical Radioisotopes, LLC, and GE Healthcare announced the signing of an exclusive agreement in the United States for the manufacture and marketing of iodine-123 (I-123) capsules. Under the terms of the agreement, GE Healthcare's Pharmaceutical Diagnostics unit will manufacture and supply NorthStar with I-123 capsules under the NorthStar label at its plant in Arlington Heights, Illinois, employing a new, cutting-edge production method.
- March 2021: Bracco Diagnostics Inc., a subsidiary of Bracco Imaging S.p.A. in the United States, announced a new cooperation with CardioNavix, LLC to improve patient access to cardiac PET imaging, a crucial diagnostic test for the diagnosis of coronary artery disease (CAD). The Bracco Mobile Isotope Service, a new program, will allow more patient care sites, such as community hospitals, physician practices, and outpatient imaging centres, to offer cardiac PET imaging.
- March 2021: BWXT Medical Ltd. and Global Medical Solutions, Ltd. have formed a joint venture in Asia to manufacture and distribute radioisotopes and radiopharmaceuticals. BWXT is now establishing operations in North America for molybdenum irradiation and the production of technetium-99m (Tc-99m) generators, which the JV intends to replicate in Asia.
An Expert’s Eye
Demand and Future Growth
An increased prevalence of cancer and chronic diseases is driving the market. The rising demand for target disease treatment may result in a growth in alpha emitters, where therapeutic nuclear medicine is favoured in large quantities, increasing the need for nuclear medicine.
Furthermore, technological developments have greatly aided the growth and development of various nuclear medicine in the medical sector. However, the nuclear medicine market is expected to face considerable challenges because of the high cost of nuclear diagnostic equipment.
Supply Side of the Market
According to our analysis, the manufacturers present in the nuclear medicine market are focusing on enhancing the medicine capacities and efficacy by introducing advanced products, mostly in therapeutic nuclear medicine, which will help patients tackle chronic diseases more effectively.
The US is the leading manufacturer and consumer of nuclear medicine worldwide. Every year, radiopharmaceuticals and imaging devices are used in about 20 million nuclear medicine treatments in the US alone. Along with this, China, in the Asia Pacific region, is growing at the fastest rate due to the growing export of medicinal raw materials to neighbouring countries.
In FY19, China supplied India with APIs worth Rs 17,400 crore. Furthermore, the growing penetration of nuclear diagnostic equipment among the Chinese population will increase the demand for nuclear medicine in China. 14,095 PET/MRI tests were performed overall in 2019 in China. The total number of SPECT exams performed in 2019 was 2.51 million, an increase of 19.9% from the previous year.
Global Nuclear Medicine Market is Categorised as Below:
By Product Type:
- Diagnostics
- Single Photon Emission Computed Tomography (SPECT)
- Positron Emission Tomography (PET)
- Therapeutics
- Alpha Emitters
- Beta Emitters
- Brachytherapy
By Application:
- Cardiology
- Neurology
- Oncology
- Thyroid
- Lymphoma
- Other Application
By End User:
- Hospitals & Clinics
- Diagnostic Centres
- Others
By Geographic Coverage:
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Turkey
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Egypt
- Nigeria
- Rest of Middle East & Africa
1. Executive Summary
1.1. Global Nuclear Medicine Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Nuclear Medicine Market Outlook, 2018 - 2030
3.1. Global Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Diagnostics
3.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
3.1.1.1.2. Positron Emission Tomography (PET)
3.1.1.2. Therapeutics
3.1.1.2.1. Alpha Emitters
3.1.1.2.2. Beta Emitters
3.1.1.2.3. Brachytherapy
3.2. Global Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Cardiology
3.2.1.2. Neurology
3.2.1.3. Oncology
3.2.1.4. Thyroid
3.2.1.5. Lymphoma
3.2.1.6. Other Application
3.3. Global Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. Hospitals & Clinics
3.3.1.2. Diagnostic Centres
3.3.1.3. Others
3.4. Global Nuclear Medicine Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Nuclear Medicine Market Outlook, 2018 - 2030
4.1. North America Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Diagnostics
4.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
4.1.1.1.2. Positron Emission Tomography (PET)
4.1.1.2. Therapeutics
4.1.1.2.1. Alpha Emitters
4.1.1.2.2. Beta Emitters
4.1.1.2.3. Brachytherapy
4.2. North America Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Cardiology
4.2.1.2. Neurology
4.2.1.3. Oncology
4.2.1.4. Thyroid
4.2.1.5. Lymphoma
4.2.1.6. Other Application
4.3. North America Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. Key Highlights
4.3.1.2. Hospitals & Clinics
4.3.1.3. Diagnostic Centres
4.3.1.4. Others
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
4.4.1. Key Highlights
4.4.1.1. U.S. Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
4.4.1.2. U.S. Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
4.4.1.3. U.S. Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
4.4.1.4. Canada Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
4.4.1.5. Canada Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
4.4.1.6. Canada Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Nuclear Medicine Market Outlook, 2018 - 2030
5.1. Europe Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Diagnostics
5.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
5.1.1.1.2. Positron Emission Tomography (PET)
5.1.1.2. Therapeutics
5.1.1.2.1. Alpha Emitters
5.1.1.2.2. Beta Emitters
5.1.1.2.3. Brachytherapy
5.2. Europe Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Cardiology
5.2.1.2. Neurology
5.2.1.3. Oncology
5.2.1.4. Thyroid
5.2.1.5. Lymphoma
5.2.1.6. Other Application
5.3. Europe Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Hospitals & Clinics
5.3.1.2. Diagnostic Centres
5.3.1.3. Others
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
5.4.1. Key Highlights
5.4.1.1. Germany Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
5.4.1.2. Germany Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
5.4.1.3. Germany Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
5.4.1.4. U.K. Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
5.4.1.5. U.K. Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
5.4.1.6. U.K. Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
5.4.1.7. France Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
5.4.1.8. France Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
5.4.1.9. France Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
5.4.1.10. Italy Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
5.4.1.11. Italy Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
5.4.1.12. Italy Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
5.4.1.13. Turkey Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
5.4.1.14. Turkey Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
5.4.1.15. Turkey Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
5.4.1.16. Russia Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
5.4.1.17. Russia Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
5.4.1.18. Russia Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
5.4.1.19. Rest of Europe Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
5.4.1.20. Rest of Europe Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
5.4.1.21. Rest of Europe Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Nuclear Medicine Market Outlook, 2018 - 2030
6.1. Asia Pacific Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Diagnostics
6.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
6.1.1.1.2. Positron Emission Tomography (PET)
6.1.1.2. Therapeutics
6.1.1.2.1. Alpha Emitters
6.1.1.2.2. Beta Emitters
6.1.1.2.3. Brachytherapy
6.2. Asia Pacific Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Cardiology
6.2.1.2. Neurology
6.2.1.3. Oncology
6.2.1.4. Thyroid
6.2.1.5. Lymphoma
6.2.1.6. Other Application
6.3. Asia Pacific Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. Hospitals & Clinics
6.3.1.2. Diagnostic Centres
6.3.1.3. Others
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
6.4.1. Key Highlights
6.4.1.1. China Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
6.4.1.2. China Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
6.4.1.3. China Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
6.4.1.4. Japan Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
6.4.1.5. Japan Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
6.4.1.6. Japan Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
6.4.1.7. South Korea Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
6.4.1.8. South Korea Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
6.4.1.9. South Korea Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
6.4.1.10. India Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
6.4.1.11. India Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
6.4.1.12. India Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
6.4.1.13. Southeast Asia Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
6.4.1.14. Southeast Asia Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
6.4.1.15. Southeast Asia Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
6.4.1.16. Rest of Asia Pacific Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
6.4.1.17. Rest of Asia Pacific Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
6.4.1.18. Rest of Asia Pacific Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Nuclear Medicine Market Outlook, 2018 - 2030
7.1. Latin America Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Diagnostics
7.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
7.1.1.1.2. Positron Emission Tomography (PET)
7.1.1.2. Therapeutics
7.1.1.2.1. Alpha Emitters
7.1.1.2.2. Beta Emitters
7.1.1.2.3. Brachytherapy
7.2. Latin America Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Cardiology
7.2.1.2. Neurology
7.2.1.3. Oncology
7.2.1.4. Thyroid
7.2.1.5. Lymphoma
7.2.1.6. Other Application
7.3. Latin America Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Hospitals & Clinics
7.3.1.2. Diagnostic Centres
7.3.1.3. Others
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
7.4.1. Key Highlights
7.4.1.1. Brazil Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
7.4.1.2. Brazil Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
7.4.1.3. Brazil Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
7.4.1.4. Mexico Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
7.4.1.5. Mexico Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
7.4.1.6. Mexico Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
7.4.1.7. Argentina Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
7.4.1.8. Argentina Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
7.4.1.9. Argentina Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
7.4.1.10. Rest of Latin America Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
7.4.1.11. Rest of Latin America Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
7.4.1.12. Rest of Latin America Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Nuclear Medicine Market Outlook, 2018 - 2030
8.1. Middle East & Africa Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Diagnostics
8.1.1.1.1. Single Photon Emission Computed Tomography (SPECT)
8.1.1.1.2. Positron Emission Tomography (PET)
8.1.1.2. Therapeutics
8.1.1.2.1. Alpha Emitters
8.1.1.2.2. Beta Emitters
8.1.1.2.3. Brachytherapy
8.2. Middle East & Africa Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Cardiology
8.2.1.2. Neurology
8.2.1.3. Oncology
8.2.1.4. Thyroid
8.2.1.5. Lymphoma
8.2.1.6. Other Application
8.3. Middle East & Africa Nuclear Medicine Market Outlook, by End User Assessment, Value (US$ Bn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. Hospitals & Clinics
8.3.1.2. Diagnostic Centres
8.3.1.3. Others
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
8.4.1. Key Highlights
8.4.1.1. GCC Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
8.4.1.2. GCC Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
8.4.1.3. GCC Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
8.4.1.4. South Africa Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
8.4.1.5. South Africa Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
8.4.1.6. South Africa Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
8.4.1.7. Egypt Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
8.4.1.8. Egypt Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
8.4.1.9. Egypt Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
8.4.1.10. Nigeria Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
8.4.1.11. Nigeria Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
8.4.1.12. Nigeria Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
8.4.1.13. Rest of Middle East & Africa Nuclear Medicine Market by Application, Value (US$ Bn), 2018 - 2030
8.4.1.14. Rest of Middle East & Africa Nuclear Medicine Market by Product Type, Value (US$ Bn), 2018 - 2030
8.4.1.15. Rest of Middle East & Africa Nuclear Medicine Market by End User Assessment, Value (US$ Bn), 2018 - 2030
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs Product/Application Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Advanced Accelerator Applications
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Norgine B.V.
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Blue Earth Diagnostics Ltd.
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Curium Pharma
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Digirad Corporation
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Jubilant Radiopharma
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Karyopharm
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Lantheus Holdings, Inc.
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Northstar Nuclear Medicine
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Business Strategies and Development
9.4.10. Precirix NV
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Sinotau Pharmaceuticals
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Solcom
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Zionexa
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
9.4.14. Cardinal Health
9.4.14.1. Company Overview
9.4.14.2. Product Portfolio
9.4.14.3. Financial Overview
9.4.14.4. Business Strategies and Development
9.4.15. Bracco Diagnostic Inc.
9.4.15.1. Company Overview
9.4.15.2. Product Portfolio
9.4.15.3. Financial Overview
9.4.15.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2022 |
 |
2018 - 2022 |
 |
2023 - 2030 |
Value: US$ Million |
|
REPORT FEATURES |
DETAILS |
|
Product Type Coverage |
|
|
Application Coverage |
|
|
End User Coverage |
|
|
Geographical Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2021), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Quality assured
